title: Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy.
mesh_terms: D000284:Administration, Oral; D017326:Clinical Trials, Phase III as Topic / Q000639:trends*; D000069462:Dimethyl Fumarate; D004345:Drug Industry / Q000639:trends*; D005650:Fumarates / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D005650:Fumarates; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D000069462:Dimethyl Fumarate